Literature DB >> 14644570

Photodegradation pathways and the in vitro phototoxicity of pyrazinamide, a phototoxic antitubercular drug.

Franklin Vargas1, Carlos Rivas, Yrene Díaz, Alberto Fuentes.   

Abstract

The phototoxic antitubercular drug pyrazinamide (1) is photolabile under irradiation with UV-A light as well as with a N2 laser (at 337 nm) in aerobic conditions. Irradiation in methanolic and in aqueous solutions of 1 produces four and three photoproducts, respectively. Their formation involves primary alpha-cleavage between the excited carbonyl of the amido group and the aromatic ring followed by hydrogen abstraction and dimerization. Pyrazinamide was able to cause photohemolysis in human erythrocytes and peroxidation of linoleic acid. Inhibition of both processes on addition of reduced glutathione (GSH) or ascorbic acid suggests the involvement of radicals. The absence of inhibition of the photohemolysis and lipid peroxidation processes in the presence of sodium azide (NaN3), or irradiation under argon, and the absence of singlet oxygen during the photolysis confirmed with 2,5-dimethylfuran rules out the possibility of participation of 1O2 in this process. Glutathione depletion was also observed. A radical intermediate was evidenced by thiobarbituric acid that was used as a radical probe, as well as by the dimerization of cysteine. No photohemolysis was detected in presence of the isolated photoproduct. We have also determined the relative efficiencies for the formation of single strand breaks after the irradiation of pBR322 DNA and pyrazinamide, which was also reduced in the presence of GSH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644570     DOI: 10.1016/j.jphotobiol.2003.09.010

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  1 in total

1.  Pyrazinamide-induced phototoxicity: a case report and review of literature.

Authors:  Subodh K Katiyar; Shailesh Bihari; Shivesh Prakash
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.